Herpes labialis 1.5 g PO (single dose)

Genital herpes recurrent in immunocompromised patients 1 g PO q12h x1d

Orolabial or genital herpes recurrent in HIV-infected 500 mg PO q8h x7d

Genital herpes suppression 250 mg PO q12h

Herpes zoster 500 mg PO q8h x7d

Safety and efficacy in pediatric patients <18y of age have not been established

Mild or moderate hepatic impairmentSevere hepatic impairmentNo dose adjustmentNo data

CrCl ≥60CrCl 40-59CrCl 20-39CrCl <20, HD1.5 g PO (single dose)750 mg PO (single dose)500 mg PO (single dose)250 mg PO (single dose)

CrCl ≥60CrCl 40-59CrCl 20-39CrCl <20, HD1 g PO q12h x1d500 mg PO q12h x1d500 mg PO (single dose)250 mg PO (single dose)

CrCl ≥40CrCl 20-39CrCl <20, HD250 mg PO q12h125 mg PO q12h125 mg PO q24h

CrCl ≥60CrCl 40-59CrCl 20-39CrCl <20, HD500 mg PO q8h500 mg PO q12h500 mg PO q24h250 mg PO q24h

General Information

  • Herpes zoster, Shingles

  • Recurrent genital herpes simplex

  • Recurrent genital herpes simplex, Suppression

  • Recurrent herpes simplex labialis

Monitor for evidence of penciclovir toxicity in patients receiving concomitant probenecid.

Monitor renal function in elderly patients.


  • Diarrhea

  • Nausea

  • Vomiting

  • Headache

  • Fatigue


  • Neutropenia

  • ALT/SGPT level raised

  • Aspartate aminotransferase serum level raised

No significant interactions

Antimicrobial class: Antiviral, Nucleoside analog

Pregnancy category: B

Average serum half life: 2.3 hours

Precautions: Acute renal failure has been reported in patients with underlying renal disease following inappropriately high doses for level of renal function; dose reduction recommended.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.